Monoclonal antibodies (mAbs) that block the PD-1:PD-L1 axis have been successfully used to unleash the full potential of tumor-reactive CTLs in cancer patients [9,10,11,12,13,14]. This evidence concerns the gene PDCD1 and cancer.